CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)

被引：1

作者：

Shitara, K. ^{[1
]}

Janjigian, Y. Y. ^{[2
]}

Elimova, E. ^{[3
]}

Zhang, J. ^{[4
]}

Chen, M-H. ^{[5
]}

Smyth, E. ^{[6
]}

Lee, J. ^{[7
]}

Miao, R. ^{[8
]}

Liu, S. ^{[8
]}

Holmblad, M. ^{[9
]}

Xu, R-H. ^{[10
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[2] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, 1275 York Ave, New York, NY 10021 USA

[3] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

[4] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept Oncol, Shanghai, Peoples R China

[5] Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan

[6] Oxford Univ Hosp NHS Fdn Trust, Dept Oncol, Oxford, England

[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[8] AstraZeneca, R&D China, Shanghai, Peoples R China

[9] AstraZeneca, Oncol R&D, Late Stage Dev, Gaithersburg, MD USA

[10] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China, Dept Med Oncol,Canc Ctr, Guangzhou, Peoples R China

来源：

关键词：

D O I：

10.1016/j.annonc.2024.05.407

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

495TiP

引用

页码：S196 / S197

页数：2